These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19428868)

  • 1. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.
    Takahashi T; Joshi SG; Al-Saleem F; Ancharski D; Singh A; Nasser Z; Simpson LL
    Vaccine; 2009 Apr; 27(19):2616-24. PubMed ID: 19428868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.
    Sheridan RE; Deshpande SS; Amersdorfer P; Marks JD; Smith T
    Toxicon; 2001 May; 39(5):651-7. PubMed ID: 11072043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
    Park JB; Simpson LL
    Infect Immun; 2003 Mar; 71(3):1147-54. PubMed ID: 12595426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The life history of a botulinum toxin molecule.
    Simpson L
    Toxicon; 2013 Jun; 68():40-59. PubMed ID: 23518040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.
    Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR
    Crit Rev Immunol; 2007; 27(4):319-41. PubMed ID: 18197812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
    Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
    J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
    Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
    Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.
    Sepulveda J; Mukherjee J; Tzipori S; Simpson LL; Shoemaker CB
    Infect Immun; 2010 Feb; 78(2):756-63. PubMed ID: 19917718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments.
    Joshi SG; Elias M; Singh A; Al-Saleem FH; Ancharski D; Nasser Z; Takahashi T; Simpson LL
    Neuroscience; 2011 Apr; 179():208-22. PubMed ID: 21277940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A.
    Yu YZ; Ma Y; Chen YX; Gong ZW; Wang S; Yu WY; Sun ZW
    Hum Vaccin; 2011 Oct; 7(10):1090-5. PubMed ID: 21941093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine.
    Elias M; Al-Saleem F; Ancharski DM; Singh A; Nasser Z; Olson RM; Simpson LL
    J Pharmacol Exp Ther; 2011 Mar; 336(3):605-12. PubMed ID: 21106906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of an immune response by oral administration of recombinant botulinum toxin.
    Kiyatkin N; Maksymowych AB; Simpson LL
    Infect Immun; 1997 Nov; 65(11):4586-91. PubMed ID: 9353037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.
    Li M; Lee D; Obi CR; Freeberg JK; Farr-Jones S; Tomic MT
    PLoS One; 2018; 13(5):e0197011. PubMed ID: 29746518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.
    Ravichandran E; Al-Saleem FH; Ancharski DM; Elias MD; Singh AK; Shamim M; Gong Y; Simpson LL
    Infect Immun; 2007 Jun; 75(6):3043-54. PubMed ID: 17371853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
    Shone C; Agostini H; Clancy J; Gu M; Yang HH; Chu Y; Johnson V; Taal M; McGlashan J; Brehm J; Tong X
    Infect Immun; 2009 Jul; 77(7):2795-801. PubMed ID: 19398544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route.
    Al-Saleem FH; Ancharski DM; Joshi SG; Elias M; Singh A; Nasser Z; Simpson LL
    Infect Immun; 2012 Dec; 80(12):4133-42. PubMed ID: 22966044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations.
    Torgeman A; Ozeri E; Ben David A; Diamant E; Rosen O; Schwartz A; Barnea A; Makovitzki A; Mimran A; Zichel R
    Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28555060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare.
    Al-Saleem FH; Nasser Z; Olson RM; Cao L; Simpson LL
    J Pharmacol Exp Ther; 2011 Aug; 338(2):503-17. PubMed ID: 21586604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.